News
This Gene Therapy Can Restore Vision, but Will It Break the Bank?
In October, Spark Therapeutics (NASDAQ: ONCE) took another step closer to FDA approval for its vision-restoring drug, Luxturna. An approval for the gene-editing therapy early next year would be a....
Why Five Prime Therapeutics Stock Is on the Rebound Today
After a whopping 41% drop yesterday, shares of the clinical-stage biotech Five Prime Therapeutics (NASDAQ: FPRX) are on the mend today as the result of an upbeat clinical update. Specifically,....
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Shares of Pacira Pharmaceuticals (NASDAQ: PCRX), which focuses on developing medicines to be used in the ambulatory or surgical setting, surged by as much as 24% during Wednesday's trading session....
Why Nektar Therapeutics Shares Are Soaring 13% Higher
After the company reported third-quarter earnings that were better than industry watchers' forecasts, shares in Nektar Therapeutics (NASDAQ: NKTR) are popping 13.1% higher today as of 2:45 p.m.....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
BASTIDE : Communiqué de mise à disposition des documents preparatoires AG du 30 novembre 2017
Société anonyme au capital de 3.303.261 euros
Siège social :
12, avenue de la Dame - Zone euro 2000
30132 CAISSARGUES
305 635 039 RCS NÎMES
ASSEMBLEE GENERALE DU 30 NOVEMBRE 2017
MODALITES DE....
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more....
BASTIDE : Nombre d'actions et de droits de vote au jour de l'avis de réunion (25.10.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Droits de vote....
How to Invest in Biotech Stocks
$33,800.That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago.Sound enticing? How about $154,980?Continue readingSource: Fool.com
Here's Why Editas Medicine Collapsed at Market Open Today
Shares of CRISPR gene-editing pioneer Editas Medicine (NASDAQ: EDIT) fell 12.1% shortly after the market opened Wednesday morning. Why? Although the company reported third-quarter 2017 earnings....
Mazor Robotics Enters a New Era
Mazor Robotics (NASDAQ: MZOR), a robotic surgery company focused on spine and brain procedures, reported its third-quarter results on Tuesday, Nov 7th. Revenue more than doubled, margins expanded,....
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
BASTIDE : Correctif à l'avis de réunion du 25.10.2017 (Ag 30.11.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Rectificatif à....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Keryx Pharmaceuticals' (NASDAQ: KERX) Auryxia just won the Food and Drug Administration (FDA) green light for boosting iron levels in non-dialysis chronic kidney disease patients, but shares....
BASTIDE : Avis de convocation à l'Assemblée Générale du 30 novembre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
305 635 039 RCS NIMES
AVIS DE....
Why Neos Therapeutics Inc Rose 13.7% In October
Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P....
3 Unknown, but Amazing, Dividend Stocks
While most income investors focus their time studying large-cap stocks, it's worth remembering that there are scores of small-cap dividend stocks that are worthy of consideration, too. Which....
Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit....
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the....